(mentions CMT) Jacques Attali Appointed to the Board of Directors at the Biophar

[Guest guest]

Jacques Attali Appointed to the Board of Directors at the Biopharma

Start-up Company Pharnext

http://www.pharmalive.com/News/index.cfm?

articleid=497387 & categoryid=33%2C34

http://www.pharmaxon.com/#

PARIS, Santé Cochin business incubator, December 4, 2007 – Pharnext,

a biopharmaceutical company specializing in the development of

innovative treatments for severe neurological diseases, has today

announced the appointment of Jacques Attali to its Board of

Directors.

" I am very pleased that Jacques Attali has agreed to join the

Pharnext Board, which will benefit from his internationally

acknowledged skills, vast experience, extensive knowledge and

visionary insight in finance and economics. This is a significant

boost for our corporate development " , stated Professor Cohen,

Pharnext's co-founder, Chairman and CEO

" I am both delighted and excited to link up with a team known for

its excellence and which is launching itself so wholeheartedly into

a new adventure at the forefront of today's revolution in

healthcare, " commented Jacques Attali.

In addition to being an academic, a writer, a man of letters and a

former advisor to the late French President François Mitterrand,

Jacques Attali founded and served as the first ever Chairman of the

European Bank for Reconstruction and Development (EBRD). He also

founded the international consultancy firm A & A (specializing in

strategic consulting, financial engineering and M & A activities) in

1994 and PlaNet Finance (a not-for-profit non-governmental

organization which aims to alleviate poverty by developing

microcredit schemes in over 60 countries worldwide) in Paris in 1998.

As prolific writer, Jacques Attali has published 43 books, including

essays, historical, political and economic works, his memoires

(`Verbatim'), plays, biographies and children's stories.

Jacques Attali holds a PhD in Economic Science and is a graduate of

the Ecole Polytechnique, the Ecole des Mines, Sciences Po and the

ENA.

About Pharnext

Founded in July 2007, Pharnext is a biopharmaceutical company

specializing in drug repositioning - the development of innovative

treatments based on existing drugs with known, acceptable toxicity

profiles.

Pharnext is focusing on severe neurodegenerative diseases in general

and peripheral neuropathies in particular - conditions which affect

hundreds of millions of people worldwide. The initial target

pathologies include Charcot-Marie-Tooth disease, an incapacitating

orphan disease which affects 30,000 people in France, followed by

related but more common diseases such as diabetic and toxic

peripheral neuropathies. Pharnext will then rapidly broaden out its

strategy to include other handicapping or life-threatening

conditions, such as Alzheimer's disease.